On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

An auto-recruit program improved DXA screening and bone health management in men with prostate cancer receiving androgen-deprivation therapy.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Opens in a new tab or window or on the link below. Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however ...

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

A MAN suffering from a common cancer was forced to have his entire penis amputated after it spread to his manhood, in what ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...